Commentary: IL-4 and IL-13 receptors and signaling

Cytokine

Volumn 75, Issue 1, 2015, Pages 38-50

  McCormick, Sarah M ^a   Heller, Nicola M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Interleukin 13; Interleukin 4; Receptor; Regulation; Singling

Indexed keywords

CYTOKINE RECEPTOR; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 RECEPTOR; RECEPTOR SUBUNIT; CYTOKINE; IL4R PROTEIN, HUMAN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN-13 RECEPTOR, HUMAN;

ALLERGY; ARTICLE; ATOPY; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; COGNITIVE DEFECT; FETUS DEVELOPMENT; HUMAN; LIGAND BINDING; LUNG FIBROSIS; NATURAL KILLER CELL; NEOPLASM; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; BRAIN; CELL DIFFERENTIATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; INFLAMMATION; METABOLISM; MOUSE; PHENOTYPE; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MICE; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-13; SIGNAL TRANSDUCTION;

EID: 84938764372     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.05.023     Document Type: Article

References (183)

1. Gadani S.P., Cronk J.C., Norris G.T., Kipnis J. Interleukin-4: a cytokine to remember. J Immunol (Baltimore, Md.: 1950) 2012, 189:4213-4219.
2. McKenzie Andrew N.J., Spits H., Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity 2014, 41:366-374.
3. Hams E., Fallon P.G. Innate type 2 cells and asthma. Curr Opin Pharmacol 2012, 12:503-509.
4. Junttila I.S., Creusot R.J., Moraga I., Bates D.L., Wong M.T., Alonso M.N., et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 2012, 8:990-998.
5. Heller NM, Dasgupta P, Dorsey NJ, Chapoval SP, Keegan AD. The type I and type II receptor complexes for IL-4 and IL-13 differentially regulate allergic lung inflammation, allergic diseases. In: Pereira C, editor. Highlights in the clinic, mechanisms and treatment; 2012. http://www.intechopen.com/books/allergic-diseases-highlights-in-the-clinic-mechanisms-and-treatment/the-type-i-and-type-ii-receptor-complexes-for-il-4-and-il-13-differentially-regulate-allergic-lung-i.
6. Sun X.J., Wang L.-M., Zhang Y., Yenush L., Myers M.G., Glasheen E., et al. Role of IRS-2 in insulin and cytokine signalling. Nature 1995, 377:173-177.
7. Dhand R., Hiles I., Panayotou G., Roche S., Fry M.J., Gout I., et al. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J 1994, 13:522-533.
8. Ruckerl D., Jenkins S.J., Laqtom N.N., Gallagher I.J., Sutherland T.E., Duncan S., et al. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 2012, 120:2307-2316.
9. Heller N.M., Qi X., Gesbert F., Keegan A.D. The extracellular and transmembrane domains of the gammaC and interleukin (IL)-13 receptor alpha1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13. J Biol Chem 2012, 287:31948-31961.
10. Karlsson H.R., Zierath J. Insulin signaling and glucose transport in insulin resistant human skeletal muscle. Cell Biochem Biophys 2007, 48:103-113.
11. Landis J., Shaw L.M. Insulin receptor substrate-2 mediated phosphatidylinositol-3-kinase signaling selectively inhibits glycogen synthase kinase-3β to regulate aerobic glycolysis. J Biol Chem 2014, 289:18603-18613.
12. Russo S.J., Bolanos C.A., Theobald D.E., DeCarolis N.A., Renthal W., Kumar A., et al. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci 2007, 10:93-99.
13. Mikita T., Campbell D., Wu P., Williamson K., Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 1996, 16:5811-5820.
14. Shen C.-H., Stavnezer J. Interaction of stat6 and NF-κB: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol 1998, 18:3395-3404.
15. Delphin S., Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-IL-4, a C/EBP family member and NF-kappa B/p50. J Exp Med 1995, 181:181-192.
16. Hallett M.A., Venmar K.T., Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res 2012, 72:6338-6343.
17. Jenkins S.J., Ruckerl D., Thomas G.D., Hewitson J.P., Duncan S., Brombacher F., et al. IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. J Exp Med 2013, 210:2477-2491.
18. Lupardus P.J., Birnbaum M.E., Garcia K.C. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2. Structure (London, England: 1993) 2010, 18:332-342.
19. Silvestri T., Pulsatelli L., Dolzani P., Facchini A., Meliconi R. Elevated serum levels of soluble interleukin-4 receptor in osteoarthritis. Osteoarthr Cartilage/OARS, Osteoarthr Res Soc 2006, 14:717-719.
20. Sato T.A., Widmer M.B., Finkelman F.D., Madani H., Jacobs C.A., Grabstein K.H., et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993, 150:2717-2723.
21. Andrews A.-L., Holloway J.W., Holgate S.T., Davies D.E. IL-4 receptor α is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006, 176:7456-7461.
22. Daines M.O., Tabata Y., Walker B.A., Chen W., Warrier M.R., Basu S., et al. Level of expression of IL-13Rα2 impacts receptor distribution and IL-13 signaling. J Immunol 2006, 176:7495-7501.
23. Sivaprasad U., Warrier M.R., Gibson A.M., Chen W., Tabata Y., Bass S.A., et al. IL-13Rα2 has a protective role in a mouse model of cutaneous inflammation. J Immunol 2010, 185:6802-6808.
24. O'Toole M., Legault H., Ramsey R., Wynn T.A., Kasaian M.T. A novel and sensitive ELISA reveals that the soluble form of IL-13R-α2 is not expressed in plasma of healthy or asthmatic subjects. Clin Exp Allergy: J Br Soc Allergy Clin Immunol 2008, 38:594-601.
25. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970.
26. Nestor C.E., Dadfar E., Ernerudh J., Gustafsson M., Bjorkander J., Benson M., et al. Sublingual immunotherapy alters expression of IL-4 and its soluble and membrane-bound receptors. Allergy 2014, 69:1564-1566.
27. Benson M., Strannegard I.L., Wennergren G., Strannegard O. Increase of the soluble IL-4 receptor (IL-4sR) and positive correlation between IL-4sR and IgE in nasal fluids from school children with allergic rhinitis. Allergy Asthma Proc: Off J Region State Allergy Soc 2000, 21:89-95.
28. Doucet C., Giron-Michel J., Canonica G.W., Azzarone B. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha. Eur J Immunol 2002, 32:2437-2449.
29. Yamamoto S., Kobayashi I., Tsuji K., Nishi N., Muro E., Miyazaki M., et al. Upregulation of interleukin-4 receptor by interferon-gamma: enhanced interleukin-4-induced eotaxin-3 production in airway epithelium. Am J Respir Cell Mol Biol 2004, 31:456-462.
30. Bani L., David D., Fevrier M., Pialoux G., Dupont B., Sugamura K., et al. Interleukin-2 receptor beta and gamma chain dysregulation during the inhibition of CD4 T cell activation by human immunodeficiency virus-1 gp120. Eur J Immunol 1997, 27:2188-2194.
31. Siegmund R., Vogelsang H., Machnik A., Herrmann D. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000, 106:1190-1195.
32. van der Velden V.H., Naber B.A., Wierenga-Wolf A.F., Debets R., Savelkoul H.F., Overbeek S.E., et al. Interleukin 4 receptors on human bronchial epithelial cells. An in vivo and in vitro analysis of expression and function. Cytokine 1998, 10:803-813.
33. Koller F.L., Hwang D.G., Dozier E.A., Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 2010, 31:1010-1017.
34. Joshi B.H., Leland P., Lababidi S., Varrichio F., Puri R.K. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med 2014, 3:1615-1628.
35. Burt B.M., Bader A., Winter D., Rodig S.J., Bueno R., Sugarbaker D.J. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res 2012, 18:1568-1577.
36. Venmar K.T., Carter K.J., Hwang D.G., Dozier E.A., Fingleton B. IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res 2014, 74:4329-4340.
37. Lyons A., Downer E.J., Crotty S., Nolan Y.M., Mills K.H.G., Lynch M.A. CD200 ligand-receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci 2007, 27:8309-8313.
38. Walker D.G., Dalsing-Hernandez J.E., Campbell N.A., Lue L.-F. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009, 215:5-19.
39. Cao C., Arendash G.W., Dickson A., Mamcarz M.B., Lin X., Ethell D.W. Aβ-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 2009, 34:63-70.
40. Natoli A., Lüpertz R., Merz C., Müller W.W., Köhler R., Krammer P.H., et al. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer 2013, 133:1945-1954.
41. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006, 9:268-275.
42. Wolf S.A., Steiner B., Akpinarli A., Kammertoens T., Nassenstein C., Braun A., et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J Immunol 2009, 182:3979-3984.
43. Derecki N.C., Cardani A.N., Yang C.H., Quinnies K.M., Crihfield A., Lynch K.R., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 2010, 207:1067-1080.
44. Verbitsky M., Yonan A.L., Malleret G., Kandel E.R., Gilliam T.C., Pavlidis P. Altered hippocampal transcript profile accompanies an age-related spatial memory deficit in mice. Learn Memory 2004, 11:253-260.
45. Zahn J.M., Poosala S., Owen A.B., Ingram D.K., Lustig A., Carter A., et al. AGEMAP: a gene expression database for aging in mice. PLoS Genet 2007, 3:e201.
46. Lynch M.A. Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci 2010, 1:6.
47. Falcone M., Rajan A.J., Bloom B.R., Brosnan C.F. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 1998, 160:4822-4830.
48. Sofroniew M.V. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 2015, 16:249-263.
49. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., et al. Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. J Neuroimmunol 2002, 126:50-57.
50. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspect Med 2012, 2:a006346.
51. Perry V.H. Innate inflammation in Parkinson's disease. Cold Spring Harbor Perspect Med 2012, 2.
52. Liu H., Prayson R.A., Estes M.L., Drazba J.A., Barnett G.H., Bingaman W., et al. In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine 2000, 12:1656-1661.
53. Ponomarev E.D., Maresz K., Tan Y., Dittel B.N. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 2007, 27:10714-10721.
54. Brodie C., Goldreich N., Haiman T., Kazimirsky G. Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion. J Neuroimmunol 1998, 81:20-30.
55. Awatsuji H., Furukawa Y., Hirota M., Murakami Y., Nii S., Furukawa S., et al. Interleukin-4 and -5 as modulators of nerve growth factor synthesis/secretion in astrocytes. J Neurosci Res 1993, 34:539-545.
56. Hu S., Sheng W.S., Peterson P.K., Chao C.C. Differential regulation by cytokines of human astrocyte nitric oxide production. Glia 1995, 15:491-494.
57. Kiyota T., Okuyama S., Swan R.J., Jacobsen M.T., Gendelman H.E., Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 2010, 24:3093-3102.
58. Shimizu E., Kawahara K., Kajizono M., Sawada M., Nakayama H. IL-4-induced selective clearance of oligomeric β-amyloid peptide1-42 by rat primary type 2 microglia. J Immunol 2008, 181:6503-6513.
59. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Multiple Scler J 2011, 17:2-15.
60. Butovsky O., Landa G., Kunis G., Ziv Y., Avidan H., Greenberg N., et al. Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J Clin Investig 2006, 116:905-915.
61. Walsh J.T., Hendrix S., Boato F., Smirnov I., Zheng J., Lukens J.R., et al. MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J Clin Investig 2015, 125.
62. Ribizzi G., Fiordoro S., Barocci S., Ferrari E., Megna M. Cytokine polymorphisms and Alzheimer disease: possible associations. Neurol Sci 2010, 31:321-325.
63. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammat 2006, 3:27.
64. Chakrabarty P., Tianbai L., Herring A., Ceballos-Diaz C., Das P., Golde T.E. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 2012, 7:36.
65. Morrison B.E., Marcondes M.C.G., Nomura D.K., Sanchez-Alavez M., Sanchez-Gonzalez A., Saar I., et al. Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol 2012, 189:5498-5502.
66. Amano Y., Yamashita Y., Kojima K., Yoshino K., Tanaka N., Sugamura K., et al. Hrs recognizes a hydrophobic amino acid cluster in cytokine receptors during ubiquitin-independent endosomal sorting. J Biol Chem 2011, 286:15458-15472.
67. Amano Y., Yoshino K., Kojima K., Takeshita T. A hydrophobic amino acid cluster inserted into the C-terminus of a recycling cell surface receptor functions as an endosomal sorting signal. Biochem Biophys Res Commun 2013, 441:164-168.
68. Wei Q., Sha Y., Bhattacharya A., Fattah E.A., Bonilla D., Jyothula S.S.S.K., et al. Regulation of IL-4 receptor signaling by STUB1 in lung inflammation. Am J Respir Crit Care Med 2013, 189:16-29.
69. Daines M.O., Tabata Y., Walker B.A., Chen W., Warrier M.R., Basu S., et al. Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling. J Immunol 2006, 176:7495-7501.
70. Wilson M.S., Elnekave E., Mentink-Kane M.M., Hodges M.G., Pesce J.T., Ramalingam T.R., et al. IL-13Rα2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Investig 2007, 117:2941-2951.
71. Wood N., Whitters M.J., Jacobson B.A., Witek J., Sypek J.P., Kasaian M., et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α 2. J Exp Med 2003, 197:703-709.
72. Morimoto M., Zhao A., Sun R., Stiltz J., Madden K.B., Mentink-Kane M., et al. IL-13 receptor α2 regulates the immune and functional response to Nippostrongylus brasiliensis infection. J Immunol 2009, 183:1934-1939.
73. Mentink-Kane M.M., Cheever A.W., Thompson R.W., Hari D.M., Kabatereine N.B., Vennervald B.J., et al. IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 2004, 101:586-590.
74. Sivaprasad U., Warrier M.R., Gibson A.M., Chen W., Tabata Y., Bass S.A., et al. IL-13Rα2 has a protective role in a mouse model of cutaneous inflammation. J Immunol 2010, 185:6802-6808.
75. Chiaramonte M.G., Mentink-Kane M., Jacobson B.A., Cheever A.W., Whitters M.J., Goad M.E.P., et al. Regulation and function of the interleukin 13 receptor α 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003, 197:687-701.
76. Chen W., Sivaprasad U., Gibson A.M., Ericksen M.B., Cunningham C.M., Bass S.A., et al. IL-13 receptor α2 contributes to development of experimental allergic asthma. J Allergy Clin Immunol 2013, 132(951-958):e956.
77. Zhou X., Hu H., Balzar S., Trudeau J.B., Wenzel S.E. MAPK regulation of IL-4/-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts. J Immunol 2012, 188:6046-6054.
78. Chen W., Sivaprasad U., Tabata Y., Gibson A.M., Stier M.T., Finkelman F.D., et al. IL-13 receptor alpha 2 membrane and soluble isoforms differ in human and mouse. J Immunol (Baltimore, Md.: 1950) 2009, 183:7870.
79. Daines M.O., Masino J.A., Gibson A.M., Chen W., Walker B.A., Warrier M.R., et al. Distribution of IL-13Ra2: impact of allergen exposure and level of expression. J Allergy Clin Immunol 2006, 117:S148.
80. Daines M.O., Hershey G.K. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma. J Biol Chem 2002, 277:10387-10393.
81. Badalyan V., Thompson R., Addo K., Borthwick L.A., Fisher A.J., Ort T., et al. TNF-α/IL-17 synergy inhibits IL-13 bioactivity via IL-13Rα2 induction. J Allergy Clin Immunol 2014, 134(975-978):e975.
82. Chandriani S., DePianto D.J., N'Diaye E.N., Abbas A.R., Jackman J., Bevers J., et al. Endogenously expressed IL-13Rα2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol 2014, 193:111-119.
83. Andrews A.-L., Nordgren I.K., Campbell-Harding G., Holloway J.W., Holgate S.T., Davies D.E., et al. The association of the cytoplasmic domains of interleukin 4 receptor alpha and interleukin 13 receptor alpha 2 regulates interleukin 4 signaling. Mol BioSyst 2013, 9:3009-3014.
84. Zheng T., Liu W., Oh S.-Y., Zhu Z., Hu B., Homer R.J., et al. IL-13 receptor α2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 2008, 180:522-529.
85. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13[alpha]2 receptor is involved in induction of TGF-[beta]1 production and fibrosis. Nat Med 2006, 12:99-106.
86. Brunner S.M., Schiechl G., Kesselring R., Martin M., Balam S., Schlitt H.J., et al. IL-13 signaling via IL-13Rα(2) triggers TGF-β(1)-dependent allograft fibrosis. Transplant Res 2013, 2:16.
87. He Chuan H., Lee Chun G., Dela Charles S., Cruz C.-M., Lee Y., Zhou F., et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep 2013, 4:830-841.
88. Specjalski K., Jassem E. YKL-40 protein is a marker of asthma. J Asthma: Off J Assoc Care Asthma 2011, 48:767-772.
89. Konradsen J.R., James A., Nordlund B., Reinius L.E., Söderhäll C., Melén E., et al. The chitinase-like protein YKL-40: apossible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol 2013, 132(328-335):e325.
90. Lee C.G., Elias J.A. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy, Asthma Immunol Res 2010, 2:20-27.
91. Ober C., Tan Z., Sun Y., Possick J.D., Pan L., Nicolae R., et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. New Engl J Med 2008, 358:1682-1691.
92. Harving M.L., Christensen L.H., Ringsholt M., Lausten G.S., Petersen M.M. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors: an immunohistochemical study of 49 tumors. Acta Orthop 2014, 85:195-200.
93. Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013, 4:122.
94. Iwamoto F.M., Hormigo A. Unveiling YKL-40, from serum marker to target therapy in glioblastoma. Front Oncol 2014, 4:90.
95. Gállego Pérez-Larraya J., Paris S., Idbaih A., Dehais C., Laigle-Donadey F., Navarro S., et al. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer 2014, 120:3972-3980.
96. Preusser M. Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma. Nat Rev Neurol 2014, 10:681-682.
97. Schubert K., von Bonnsdorf H., Burke M., Ahlert I., Braun S., Berner R., et al. A comprehensive candidate gene study on bronchial asthma and juvenile idiopathic arthritis. Dis Markers 2006, 22:127-132.
98. Song G.G., Bae S.-C., Kim J.-H., Lee Y.H. Interleukin-4, interleukin-4 receptor, and interleukin-18 polymorphisms and rheumatoid arthritis: a meta-analysis. Immunol Invest 2013, 42:455-469.
99. Hulshof S., Montagne L., De Groot C.J.A., Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 2002, 38:24-35.
100. Sholl-Franco A., Da Silva A.G.L.S., Adão-Novaes J. Interleukin-4 as a neuromodulatory cytokine. Ann NY Acad Sci 2009, 1153:65-75.
101. Gaupp S., Cannella B., Raine C.S. Amelioration of experimental autoimmune encephalomyelitis in IL-4Rα(-/-) mice implicates compensatory up-regulation of Th2-type cytokines. Am J Pathol 2008, 173:119-129.
102. Noguchi Shibasaki, Arinami Takeda, Yokouchi Kawashima, Yanagi Matsui, Hamaguchi Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998, 28:449-453.
103. Noguchi E., Shibasaki M., Arinami T., Takeda K., Maki T., Miyamoto T., et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med 1997, 156:1390-1393.
104. Ding M., Sheng H., Shen W., Zhen J., Xi L., Zeng J., et al. Association of the SNP rs1800925(C/T) in the interleukin-13 gene promoter with pulmonary function in Chinese Han patients with idiopathic pulmonary fibrosis. Cell Biochem Biophys 2013, 67:905-909.
105. Beghé B., Hall I.P., Parker S.G., Moffatt M.F., Wardlaw A., Connolly M.J., et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy 2010, 65:474-481.
106. Nie W., Zang Y., Chen J., Xiu Q. Association between interleukin-4 receptor alpha chain (IL4RA) I50V and Q551R polymorphisms and asthma risk: an update meta-analysis. PLoS ONE 2013, 8:e69120.
107. Graves P.E., Kabesch M., Halonen M., Holberg C.J., Baldini M., Fritzsch C., et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000, 105:506-513.
108. Bugawan T.L., Mirel D.B., Valdes A.M., Panelo A., Pozzilli P., Erlich H.A. Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am J Human Genet 2003, 72:1505-1514.
109. Wenzel S.E., Balzar S., Ampleford E., Hawkins G.A., Busse W.W., Calhoun W.J., et al. IL4Rα mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007, 175:570-576.
110. Howard T.D., Koppelman G.H., Xu J., Zheng S.L., Postma D.S., Meyers D.A., et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002, 70:230-236.
111. Sun G., Wang X., Shi L., Yue X., Fu L., Chen C., et al. Association between polymorphisms in interleukin-4Ralpha and interleukin-13 and glioma risk: a meta-analysis. Cancer Epidemiol 2013, 37:306-310.
112. Guo J., Shi L., Li M., Xu J., Yan S., Zhang C., et al. Association of the interleukin-4Ralpha rs1801275 and rs1805015 polymorphisms with glioma risk. Tumour Biol: J Int Soc Oncodev Biol Med 2014, 35:573-579.
113. Ford A.Q., Heller N.M., Stephenson L., Boothby M.R., Keegan A.D. An atopy-associated polymorphism in the ectodomain of the IL-4R(alpha) chain (V50) regulates the persistence of STAT6 phosphorylation. J Immunol 2009, 183:1607-1616.
114. Yabiku K., Hayashi M., Komiya I., Yamada T., Kinjo Y., Ohshiro Y., et al. Polymorphisms of interleukin (IL)-4 receptor alpha and signal transducer and activator of transcription-6 (Stat6) are associated with increased IL-4Rα-Stat6 signalling in lymphocytes and elevated serum IgE in patients with Graves' disease. Clin Exp Immunol 2007, 148:425-431.
115. Leipe J., Schramm M.A., Prots I., Schulze-Koops H., Skapenko A. Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene, rs1805010. Arthritis Rheumatol 2014, 66:1165-1175.
116. Prots I., Skapenko A., Wendler J., Mattyasovszky S., Yone C.L., Spriewald B., et al. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006, 54:1491-1500.
117. Rahman P., Snelgrove T., Peddle L., Siannis F., Farewell V., Schentag C., et al. A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. Arthritis Rheum 2008, 58:2207-2208.
118. Burgos P.I., Causey Z.L., Tamhane A., Kelley J.M., Brown E.E., Hughes L.B., et al. Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R75.
119. Wallis S.K., Cooney L.A., Endres J.L., Lee M.J., Ryu J., Somers E.C., et al. A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R15.
120. Hage T., Sebald W., Reinemer P. Crystal structure of the interleukin-4/receptor α chain complex reveals a mosaic binding interface. Cell 1999, 97:271-281.
121. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132:259-272.
122. Pelaia G., Vatrella A., Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012, 11:958-972.
123. Hansbro P.M., Scott G.V., Essilfie A.-T., Kim R.Y., Starkey M.R., Nguyen D.H., et al. Th2 cytokine antagonists: potential treatments for severe asthma. Exp Opin Investig Drugs 2012, 22:49-69.
124. Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med 2010, 181:788-796.
125. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
126. Pfizer, W. Study evaluating the effect of IMA-638 in subjects with persistent asthma. [accessed 05.01.14]. http://clinicaltrials.gov/ct2/show/NCT00425061.
127. De Boever E.H., Ashman C., Cahn A.P., Locantore N.W., Overend P., Pouliquen I.J., et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: arandomized trial. J Allergy Clin Immunol 2014, 133(989-996):e984.
128. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
129. Maes T., Joos G.F., Brusselle G.G. Targeting interleukin-4 in asthma: lost in translation?. Am J Respir Cell Mol Biol 2012, 47:261-270.
130. Wenzel S., Wilbraham D., Fuller R., Getz E.B., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
131. Duppatla V., Gjorgjevikj M., Schmitz W., Hermanns H.M., Schäfer C.M., Kottmair M., et al. IL-4 analogues with site-specific chemical modification at position 121 inhibit IL-4 and IL-13 biological activities. Bioconjug Chem 2013, 25:52-62.
132. Slager R.E., Otulana B.A., Hawkins G.A., Yen Y.P., Peters S.P., Wenzel S.E., et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012, 130(516-522):e514.
133. Burmeister Getz E., Fisher D.M., Fuller R. Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009, 49:1025-1036.
134. Lazarski C.A., Ford J., Katzman S.D., Rosenberg A.F., Fowell D.J. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS ONE 2013, 8:e71949.
135. Hoshino A., Tsuji T., Matsuzaki J., Jinushi T., Ashino S., Teramura T., et al. STAT6-mediated signaling in Th2-dependent allergic asthma: critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. Int Immunol 2004, 16:1497-1505.
136. Heller N.M., Gwinn W.M., Donnelly R.P., Constant S.L., Keegan A.D. IL-4 engagement of the type I IL-4 receptor complex enhances mouse eosinophil migration to eotaxin-1 in vitro. PLoS ONE 2012, 7:e39673.
137. Stokes K., LaMarche N.M., Islam N., Wood A., Huang W., August A. Cutting edge: STAT6 signaling in eosinophils is necessary for development of allergic airway inflammation. J Immunol 2015, 194:2477-2481.
138. Kuperman D., Schofield B., Wills-Karp M., Grusby M.J. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998, 187:939-948.
139. Rosen M.J., Chaturvedi R., Washington M.K., Kuhnhein L.A., Moore P.D., Coggeshall S.S., et al. STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol 2013, 190:1849-1858.
140. Hanson E.M., Dickensheets H., Qu C.-K., Donnelly R.P., Keegan A.D. Regulation of the dephosphorylation of Stat6: participation of Tyr-713 in the interleukin-4 receptor α, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem 2003, 278:3903-3911.
141. Cho Y.S., Oh S.Y., Zhu Z. Tyrosine phosphatase SHP-1 in oxidative stress and development of allergic airway inflammation. Am J Respir Cell Mol Biol 2008, 39:412-419.
142. Oh S.Y., Zheng T., Kim Y.K., Cohn L., Homer R.J., McKenzie A.N., et al. A critical role of SHP-1 in regulation of type 2 inflammation in the lung. Am J Respir Cell Mol Biol 2009, 40:568-574.
143. Jang M.K., Kim S.H., Lee K.Y., Kim T.B., Moon K.A., Park C.S., et al. The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress. Biochem Biophys Res Commun 2010, 393:137-143.
144. Zhang L., Oh S.Y., Wu X., Oh M.H., Wu F., Schroeder J.T., et al. SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung. J Immunol 2010, 184:1180-1190.
145. Pao L.I., Lam K.-P., Henderson J.M., Kutok J.L., Alimzhanov M., Nitschke L., et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 2007, 27:35-48.
146. Kamata T., Yamashita M., Kimura M., Murata K., Inami M., Shimizu C., et al. Src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 2003, 111:109-119.
147. Plas D.R., Johnson R., Pingel J.T., Matthews R.J., Dalton M., Roy G., et al. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 1996, 272:1173-1176.
148. Kim C.H., Qu C.-K., Hangoc G., Cooper S., Anzai N., Feng G.-S., et al. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase Shp-1 in chemokine responses. J Exp Med 1999, 190:681-690.
149. Minoo P., Zadeh M.M., Rottapel R., Lebrun J.-J., Ali S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood 2004.
150. Cho S.H., Oh S.Y., Lane A.P., Lee J., Oh M.-H., Lee S., et al. Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways. PLoS ONE 2014, 9:e103685.
151. Zhou L., Oh S.Y., Zhou Y., Yuan B., Wu F., Oh M.H., et al. SHP-1 regulation of mast cell function in allergic inflammation and anaphylaxis. PLoS ONE 2013, 8:e55763.
152. Christophi G.P., Panos M., Hudson C.A., Christophi R.L., Gruber R.C., Mersich A.T., et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest; J Tech Methods Pathol 2009, 89:742-759.
153. Johnson D.J., Pao L.I., Dhanji S., Murakami K., Ohashi P.S., Neel B.G. Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med 2013, 210:1419-1431.
154. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
155. Christophi G.P., Hudson C.A., Gruber R.C., Christophi C.P., Mihai C., Mejico L.J., et al. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest; J Tech Methods Pathol 2008, 88:243-255.
156. Miklossy G., Hilliard T.S., Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013, 12:611-629.
157. Heller N.M., Qi X., Junttila I.S., Shirey K.A., Vogel S.N., Paul W.E., Keegan A.D. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal 2008, 1:ra17.
158. Hirashima Y., Tsuruzoe K., Kodama S., Igata M., Toyonaga T., Ueki K., et al. Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. J Endocrinol 2003, 179:253-266.
159. Rui L., Yuan M., Frantz D., Shoelson S., White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002, 277:42394-42398.
160. Kershaw N.J., Murphy J.M., Liau N.P.D., Varghese L.N., Laktyushin A., Whitlock E.L., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013, 20:469-476.
161. Whyte C.S., Bishop E.T., Rückerl D., Gaspar-Pereira S., Barker R.N., Allen J.E., et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol 2011, 90:845-854.
162. Liu Y., Stewart K.N., Bishop E., Marek C.J., Kluth D.C., Rees A.J., et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 2008, 180:6270-6278.
163. Qin H., Holdbrooks A.T., Liu Y., Reynolds S.L., Yanagisawa L.L., Benveniste E.N. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol 2012, 189:3439-3448.
164. Porter H.A., Perry A., Kingsley C., Tran N.L., Keegan A.D. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett 2013, 338:239-248.
165. Wang L.M., Keegan A.D., Paul W.E., Heidaran M.A., Gutkind J.S., Pierce J.H. IL-4 activates a distinct signal transduction cascade from IL-3 in factor-dependent myeloid cells. EMBO J 1992, 11:4899-4908.
166. Izuhara K., Harada N. Interleukin-4 (IL-4) induces protein tyrosine phosphorylation of the IL-4 receptor and association of phosphatidylinositol 3-kinase to the IL-4 receptor in a mouse T cell line, HT2. J Biol Chem 1993, 268:13097-13102.
167. Cerezo A., Martinez A.C., Lanzarot D., Fischer S., Franke T.F., Rebollo A. Role of Akt and c-Jun N-terminal kinase 2 in apoptosis induced by interleukin-4 deprivation. Mol Biol Cell 1998, 9:3107-3118.
168. Scheid M.P., Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 1998, 95:7439-7444.
169. Laplante M., Sabatini D.M. MTOR signaling at a glance. J Cell Sci 2009, 122:3589-3594.
170. Saleiro D., Platanias L.C. Intersection of mTOR and STAT signaling in immunity. Trends Immunol 2015, 36:21-29.
171. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
172. Gan X., Wang J., Su B., Wu D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 2011, 286:10998-11002.
173. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
174. Hart J.R., Vogt P.K. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011, 2:467-476.
175. Stephenson L.M., Park D.S., Mora A.L., Goenka S., Boothby M. Sequence motifs in IL-4R alpha mediating cell-cycle progression of primary lymphocytes. J Immunol 2005, 175:5178-5185.
176. Lee K., Gudapati P., Dragovic S., Spencer C., Joyce S., Killeen N., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
177. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011, 12:295-303.
178. Heikamp E.B., Patel C.H., Collins S., Waickman A., Oh M.-H., Sun I.-H., et al. The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nat Immunol 2014, 15:457-464.
179. Byles V., Covarrubias A.J., Ben-Sahra I., Lamming D.W., Sabatini D.M., Manning B.D., et al. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun 2013, 4.
180. Zhu L., Yang T., Li L., Sun L., Hou Y., Hu X., et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat Commun 2014, 5.
181. Mercalli A., Calavita I., Dugnani E., Citro A., Cantarelli E., Nano R., et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology 2013, 140:179-190.
182. Mushaben E.M., Hershey G.K., Pauciulo M.W., Nichols W.C., Le Cras T.D. Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice. PLoS ONE 2012, 7:e32468.
183. Fredricksson K., Fielhaber J.A., Lam J.K., Yao X., Meyer K.S., Keeran K.J., et al. Paradoxical effects of rapamycin on experimental house dust mite-induced asthma. PLoS ONE 2012, 7:e33984.